Surufatinib
Surufatinib is a pharmaceutical drug with 55 clinical trials. Currently 16 active trials ongoing. Historical success rate of 87.5%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
11
Early Stage
35
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
87.5%
14 of 16 finished
12.5%
2 ended early
16
trials recruiting
55
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
Clinical Trials (55)
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System
Open-label Study of Surufatinib in Japanese Patients
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
Open-Label Surufatinib in European Patients With NET
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 55